Rhenman & Partners Asset Management’s Gilead Sciences GILD Stock Holding History

Rhenman & Partners Asset Management’s Portfolio GILD Stock Details GILD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$23.4M	Buy	167,750 +41,600	+33%	+$5.83M	2.88%	6
2025 Q4	$15.5M	Buy	126,150 +46,000	+57%	+$5.59M	1.45%	29
2025 Q3	$8.9M	Sell	80,150 -88,000	-52%	-$10M	0.98%	38
2025 Q2	$18.6M	Sell	168,150 -65,350	-28%	-$6.95M	2.36%	11
2025 Q1	$26.2M	Sell	233,500 -22,000	-9%	-$2.27M	3.01%	7
2024 Q4	$23.6M	Sell	255,500 -111,000	-30%	-$9.99M	2.43%	11
2024 Q3	$30.7M	Buy	366,500 +128,000	+54%	+$9.77M	2.49%	12
2024 Q2	$16.4M	Buy	238,500 +111,500	+88%	+$7.44M	1.57%	23
2024 Q1	$9.3M	Sell	127,000 -132,000	-51%	-$10.2M	0.88%	41
2023 Q4	$21M	Buy	259,000 +25,000	+11%	+$1.95M	2.1%	16
2023 Q3	$17.5M	Hold	234,000	–	–	1.89%	22
2023 Q2	$18M	Sell	234,000 -25,000	-10%	-$1.99M	1.9%	22
2023 Q1	$21.1M	Sell	259,000 -11,000	-4%	-$911K	2.32%	19
2022 Q4	$23.2M	Hold	270,000	–	–	2.42%	8
2022 Q3	$21.2M	Buy	270,000 +70,000	+35%	+$4.41M	2.22%	15
2022 Q2	$12.4M	Buy	200,000 +30,000	+18%	+$1.86M	1.4%	29
2022 Q1	$10.1M	Sell	170,000 -105,000	-38%	-$6.71M	1%	41
2021 Q4	$20.2M	Sell	275,000 -25,000	-8%	-$1.72M	1.34%	29
2021 Q3	$21M	Hold	300,000	–	–	1.47%	25
2021 Q2	$20.7M	Sell	300,000 -50,000	-14%	-$3.34M	1.4%	28
2021 Q1	$22.6M	Sell	350,000 -35,000	-9%	-$2.26M	1.58%	24
2020 Q4	$22.4M	Buy	385,000 +95,000	+33%	+$5.73M	1.83%	17
2020 Q3	$18.3M	Buy	290,000 +60,000	+26%	+$4.16M	1.63%	24
2020 Q2	$17.7M	Buy	+230,000	New	+$17.6M	1.91%	14
2019 Q1	–	Sell	-188,200	Closed	-$11.8M	–	95
2018 Q4	$11.8M	Sell	188,200 -1,447	-0.8%	-$101K	1.35%	36
2018 Q3	$14.6M	Sell	189,647 -72,380	-28%	-$5.47M	1.47%	31
2018 Q2	$18.6M	Buy	262,027 +25,000	+11%	+$1.77M	1.9%	22
2018 Q1	$17.9M	Sell	237,027 -48,724	-17%	-$3.87M	2.2%	13
2017 Q4	$20.5M	Buy	285,751 +130,200	+84%	+$9.89M	2.77%	7
2017 Q3	$12.6M	Sell	155,551 -101,365	-39%	-$7.75M	1.61%	21
2017 Q2	$18.2M	Buy	256,916 +50,000	+24%	+$3.33M	2.61%	6
2017 Q1	$14.1M	Sell	206,916 -52,978	-20%	-$3.73M	2.23%	12
2016 Q4	$18.6M	Buy	+259,894	New	+$19.3M	3.57%	1
2016 Q3	–	Sell	-240,000	Closed	-$20M	–	112
2016 Q2	$20M	Buy	240,000 +60,000	+33%	+$5.32M	3.56%	2
2016 Q1	$16.5M	Buy	180,000 +56,000	+45%	+$5.05M	3.28%	2
2015 Q4	$12.5M	Buy	124,000 +9,000	+8%	+$936K	1.9%	13
2015 Q3	$11.3M	Sell	115,000 -15,000	-12%	-$1.67M	1.8%	22
2015 Q2	$15.2M	Sell	130,000 -29,000	-18%	-$3.17M	1.83%	12
2015 Q1	$15.6M	Sell	159,000 -47,138	-23%	-$4.79M	2.63%	8
2014 Q4	$19.4M	Buy	206,138 +134,138	+186%	+$13.9M	5.63%	2
2014 Q3	$7.66M	Sell	72,000 -108,000	-60%	-$10.6M	2.24%	7
2014 Q2	$14.9M	Sell	180,000 -68,735	-28%	-$5.35M	4.43%	3
2014 Q1	$17.6M	Buy	248,735 +139,735	+128%	+$11M	5.29%	1
2013 Q4	$8.19M	Buy	+109,000	New	+$7.59M	3.2%	3

Other funds holding GILD

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Rhenman & Partners Asset Management's GILD Position: Q1 2026 in Review

Rhenman & Partners Asset Management increased its Gilead Sciences (GILD) stake by 33% in Q1 2026, buying an estimated $5.83M and bringing the position to 167,750 shares worth $23.4M. The position accounts for 2.88% of the portfolio, ranked #6.

Rhenman & Partners Asset Management first reported a position in GILD in Q4 2013 and has held it in 44 quarters since. The position peaked at $30.7M in Q3 2024. 2,311 funds tracked by Wall St. Rank hold GILD as of Q1 2026.

Rhenman & Partners Asset Management held 167,750 shares of Gilead Sciences worth $23.4M as of Q1 2026.
Rhenman & Partners Asset Management bought 41,600 Gilead Sciences shares in Q1 2026, an estimated $5.83M.
Gilead Sciences made up 2.88% of Rhenman & Partners Asset Management's portfolio in Q1 2026, its #6 holding.
Rhenman & Partners Asset Management first reported a position in Gilead Sciences in Q4 2013 and has held it in 44 quarters since.
Rhenman & Partners Asset Management's Gilead Sciences position peaked at $30.7M in Q3 2024.
2,311 funds tracked by Wall St. Rank held Gilead Sciences as of Q1 2026.

Based on Rhenman & Partners Asset Management's 13F filing for Q1 2026, filed 14 May 2026.